AMENDMENT NO. 3 TO OPTION, LICENSE AND COLLABORATION AGREEMENTOption, License and Collaboration Agreement • February 21st, 2024 • Arcus Biosciences, Inc. • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment No. 3”) to the Option, License and Collaboration Agreement, dated as of May 27, 2020, as amended as of November 17, 2021 and May 12, 2023 (collectively, the “Agreement”), is entered into as of January 28, 2024 (the “Amendment No. 3 Execution Date”), by and between Gilead Sciences, Inc. (“Gilead”), and Arcus Biosciences, Inc. (“Arcus”). Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement to the extent defined therein.
